Cancer Therapy Market Size, Share, Forecast & Trends Analysis

The global cancer therapy market was valued at USD 221.50 billion in 2025. It is estimated at USD 240.00 billion in 2026 and is projected to reach USD 472.10 billion by 2036, growing at a CAGR of 7.0% over the 2026-2036 forecast period. This report assesses the market in depth, covering epidemiology, treatment paradigms, modality trends, the pipeline, patent expiry, pricing and reimbursement, regulation, manufacturing and isotope supply, licensing and M&A, and competition.

The study covers approved medicines and biologics used to treat cancer: targeted therapy, immunotherapy (including checkpoint inhibitors, bispecific antibodies, cell therapies, cancer vaccines, and oncolytic viruses), chemotherapy, hormonal therapy, and radioligand therapy. The market is measured at manufacturer sales. Radiotherapy equipment and services, surgery, diagnostics and companion testing, and supportive care drugs such as antiemetics are outside the scope.

According to the International Agency for Research on Cancer (IARC), there were about 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, and annual new cases are projected to exceed 35 million by 2050. Value in the market is highly concentrated: Merck reported Keytruda sales of USD 31.68 billion in 2025, and the company expects its main U.S. patent to expire in 2028, with government price setting taking effect from January 2029. Newer modalities are scaling quickly: Johnson & Johnson reported 2025 Oncology sales of USD 25.38 billion, up 22.1%, and the company reported that sales of its CAR-T therapy Carvykti rose 95.9%.

Market Dynamics

Cancer risk rises sharply with age, so aging populations in North America, Europe, and East Asia add patients each year, while longer survival means many patients receive several lines of treatment. Antibody-drug conjugates and bispecific antibodies are moving from late-line use into first- and second-line treatment, which enlarges the eligible population and lengthens time on therapy. Routine tumor sequencing directs more patients to biomarker-matched drugs, cell and radioligand therapies have become commercial modalities with high per-patient value, and wider reimbursement in China, India, Brazil, Mexico, and the Gulf states is bringing more patients into treatment.

The largest checkpoint inhibitors and monoclonal antibodies begin losing exclusivity in 2028, and biosimilars will sharply reduce revenue per patient even as volumes hold. Price negotiation in the U.S., health technology assessment in Europe, and volume-based procurement in China all weigh on realized prices. Patient-specific cell therapy manufacturing and limited isotope capacity slow scale-up, and late-stage trial failures remain costly. Further challenges include crowding around targets such as PD-1/PD-L1, HER2, TROP2, and BCMA, cross-resistance when similar drugs are given in sequence, few accredited centers for complex therapies, and the toxicity of combination regimens.

Opportunities lie in subcutaneous and oral reformulation of established biologics, radioligands for new tumor targets using alpha emitters such as actinium-225, allogeneic and in vivo cell therapy platforms, and biosimilars that reach untreated patients in emerging markets. Merck's subcutaneous Keytruda Qlex, approved by the U.S. FDA in September 2025, is protected in the U.S. until 2043. Key trends include the shift from infusion to subcutaneous dosing, earlier use of advanced modalities, the rise of Chinese biotech companies as a source of licensed assets, and the development of drugs as parts of combination regimens.

Segment Analysis

The report analyzes the market by therapy class, molecule type, route of administration, line of therapy, cancer indication, treatment setting, distribution channel, end user, and geography, helping stakeholders identify where demand and value are shifting.

By therapy class, the report covers targeted therapy, immunotherapy, chemotherapy, hormonal therapy, and radiopharmaceutical therapy. Targeted therapy is expected to hold the largest share in 2026, as kinase inhibitors, monoclonal antibodies, and antibody-drug conjugates are used across many solid tumors and blood cancers, often after biomarker testing that supports premium pricing. Radiopharmaceutical therapy is expected to grow at the highest CAGR, as radioligands expand beyond prostate and neuroendocrine cancers, alpha-emitter supply is scaled up, and large drug makers enter the field through acquisitions. Immunotherapy remains central, though branded checkpoint inhibitor revenue faces pressure from 2028.

By molecule type, the study examines monoclonal antibodies, antibody-drug conjugates, bispecific antibodies & T-cell engagers, small molecules, cell & gene therapies, and radioligands. Monoclonal antibodies are expected to lead in 2026, reflecting the scale of checkpoint inhibitors such as Keytruda and established antibodies such as Darzalex, which also serve as backbones of combination regimens. Cell & gene therapies are expected to grow at the highest CAGR, as CAR-T products such as Carvykti move into earlier lines of multiple myeloma treatment and manufacturing capacity expands.

The route of administration analysis spans intravenous, subcutaneous, oral, and intratumoural & other routes. Intravenous delivery is expected to hold the largest share in 2026, since checkpoint inhibitors, most antibodies, conjugates, and chemotherapy are infused and make up most treated volume. The subcutaneous route is expected to grow at the highest CAGR, driven by reformulated antibodies such as Keytruda Qlex that extend patent life, take minutes to give, and free infusion chairs.

By line of therapy, the report covers first line, second line, third line & later, and adjuvant & neoadjuvant use. First-line treatment is expected to hold the largest share in 2026, because checkpoint inhibitors and targeted agents are standard initial therapy in major solid tumors with the largest eligible patient pools. The adjuvant & neoadjuvant segment is expected to grow at the highest CAGR, as new approvals bring advanced modalities into early-stage disease to prevent recurrence in far larger populations.

The cancer indication analysis includes lung cancer, breast cancer, haematological malignancies, gastrointestinal cancers, genitourinary cancers, gynaecologic cancers, and other cancers. Lung cancer is expected to represent the largest share in 2026, owing to its high incidence and heavy use of checkpoint inhibitors and mutation-matched targeted drugs. Haematological malignancies are expected to grow at the highest CAGR, driven by bispecific antibodies and CAR-T therapies in multiple myeloma, lymphoma, and leukemia, where patients receive several advanced therapies in sequence. Breast cancer remains a major indication as conjugates widen options across HER2-positive, HER2-low, and triple-negative disease.

By treatment setting, the study covers hospital inpatient care, hospital outpatient & infusion centers, specialty cancer centers, and community oncology practices. Hospital outpatient & infusion centers are expected to lead in 2026, as most intravenous cancer drugs are given in outpatient infusion units. Specialty cancer centers are expected to grow at the highest CAGR, since cell and radioligand therapies require accredited sites with apheresis, cryogenic storage, intensive care support, and nuclear medicine facilities.

By distribution channel, the report covers hospital pharmacies, specialty pharmacies, and retail pharmacies. Hospital pharmacies handle infused products and the complex logistics of cell and radioligand therapies, specialty pharmacies dispense high-cost oral targeted drugs and manage payer approval and patient support, and retail pharmacies mainly supply oral hormonal agents and generics. The move toward oral and subcutaneous products is expected to raise the role of channels outside the hospital.

The end user analysis covers hospitals & cancer centers, specialty clinics, and home & ambulatory care. Hospitals & cancer centers are expected to hold the largest share in 2026, as they have the infusion capacity, monitoring, and staff needed to manage side effects across all therapy classes. Home & ambulatory care is expected to grow at the highest CAGR, supported by oral targeted drugs and short subcutaneous injections that allow treatment outside the hospital.

Regional Analysis

The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, with analysis of 22 countries, the Nordic countries, Southeast Asia, and four rest-of-region groups. The analysis considers incidence, approval timing, reimbursement, treatment infrastructure, and patent expiry timing in each market.

North America is expected to remain the largest regional market in 2026, as the U.S. receives most new oncology drugs first, pays the highest prices, has broad insurance coverage, and is home to many leading developers, although it is also where value erosion starts first, with Keytruda facing U.S. patent expiry in 2028 and price setting from 2029. Europe holds a significant share, led by Germany, France, Italy, Spain, and the U.K., with Keytruda protection lasting to 2031, although health technology assessment delays or limits uptake of some therapies.

Asia-Pacific is expected to grow at the highest CAGR during the forecast period, supported by large and rising patient numbers, expanding reimbursement, and its growing role as a source of new drugs. Chinese developers license conjugate, bispecific, and cell therapy assets to global companies, Japan hosts leading conjugate developers, and South Korea and India pair rising demand with biosimilar production. In Latin America, Brazil and Mexico are the largest markets and biosimilar entry should widen access, while in the Middle East & Africa, Gulf states are investing in comprehensive cancer centers and adopting advanced therapies early.

Competitive Landscape

The report reviews key growth strategies, competitive benchmarking, the competitive dashboard, strategic developments, and 2025 market share/rank analysis, with company profiles covering business overview, financials, product portfolio, recent developments, and SWOT analysis.

The market is led by large pharmaceutical companies with portfolios across several therapy classes, alongside cell therapy and radiopharmaceutical specialists, Chinese biotech companies licensing assets abroad, and biosimilar makers preparing for patent expiries. Keytruda is the largest single product, while Johnson & Johnson's oncology portfolio, led by Darzalex and Carvykti, is among the fastest growing. Main strategies include label expansion into first-line and adjuvant use, subcutaneous conversion of antibodies, acquisition and licensing of conjugate, bispecific, and radiopharmaceutical assets, and investment in cell therapy and isotope capacity, as seen in the 2025 U.S. approval of Keytruda Qlex.

Key companies profiled in the report include Merck & Co., Inc. (U.S.), Johnson & Johnson (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), AstraZeneca PLC (U.K.), Bristol Myers Squibb Company (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Amgen Inc. (U.S.), Sanofi S.A. (France), GSK plc (U.K.), Daiichi Sankyo Company, Limited (Japan), Gilead Sciences, Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Regeneron Pharmaceuticals, Inc. (U.S.), Genmab A/S (Denmark), Legend Biotech Corporation (China/U.S.), Advanced Accelerator Applications (Novartis) (France), BeiGene, Ltd. (BeOne Medicines) (China/Switzerland), Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China), and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (China).

How This Report Helps

Provides reliable market size estimates and long-term forecasts for the global cancer therapy market through 2036.
Explains how rising incidence, earlier use of conjugates and bispecifics, and precision oncology are shaping demand.
Assesses the impact of patent expiry, biosimilars, government price setting, and health technology assessment on market value.
Identifies high-growth opportunities across therapy class, molecule type, route, line of therapy, indication, setting, channel, end user, and region.
Tracks emerging modalities such as alpha-emitting radioligands, allogeneic and in vivo cell therapies, and subcutaneous reformulations.
Benchmarks leading companies on portfolios, pipelines, licensing and acquisition activity, and market position.
Supports portfolio planning, business development, market access, and investment decisions for drug developers, investors, and providers.

Key Questions Answered

How large is the global cancer therapy market today, and how will it grow through 2036?
How will the loss of exclusivity on Keytruda and other major biologics affect market value from 2028?
What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
How quickly are conjugates, bispecifics, cell therapies, and radioligands moving into earlier lines of treatment?
Which therapy class, molecule type, route, line of therapy, indication, and care setting will grow the fastest?
How are subcutaneous reformulation and biosimilar entry changing the economics of established biologics?
Which regions and countries offer the most attractive opportunities, and how is China's role in oncology changing?
Who are the leading companies in the market, and how do they compare?
What approvals, licensing deals, acquisitions, and capacity investments are shaping competition?

1. Introduction

1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Scope of the Study
1.5. Key Stakeholders

2. Research Methodology

2.1. Research Approach
2.2. Data Collection & Validation Process
2.2.1. Secondary Research
2.2.2. Primary Research & Validation
2.2.2.1. Primary Interviews with Industry Experts
2.2.2.2. Country-Level Incidence and Reimbursement Analysis
2.3. Market Estimation
2.3.1. Bottom-Up Approach (Treated Patients x Annual Cost of Therapy by Indication)
2.3.2. Top-Down Approach (Company Reported Product Sales by Therapy Class)
2.3.3. Forecast Methodology (Launch, Label Expansion and Loss of Exclusivity Modelling)
2.4. Data Triangulation
2.5. Assumptions

3. Executive Summary

3.1. Key Findings
3.2. Market Snapshot
3.3. Strategic Insights
3.4. Analyst Perspective

4. Market Insights

4.1. Industry Overview
4.2. Cancer Epidemiology and Disease Burden
4.2.1. Global Incidence and Mortality Trends
4.2.2. Incidence by Tumour Type
4.2.3. Regional Incidence and Survival Disparities
4.2.4. Projected Incidence to 2050
4.3. Treatment Paradigm Analysis
4.3.1. Standard of Care by Major Indication
4.3.2. Movement of Advanced Modalities into Earlier Lines
4.3.3. Combination Regimen Architecture
4.3.4. Treatment Sequencing and Resistance Mechanisms
4.4. Technology and Modality Landscape
4.4.1. Immune Checkpoint Inhibition
4.4.2. Antibody-Drug Conjugate Technology
4.4.2.1. Targets and Payload Classes
4.4.2.2. Linker and Conjugation Platforms
4.4.3. Bispecific Antibodies and T-Cell Engagers
4.4.4. Cell Therapy Platforms
4.4.4.1. Autologous CAR-T
4.4.4.2. Allogeneic and Off-the-Shelf Cell Therapy
4.4.4.3. In Vivo Cell Engineering
4.4.4.4. TIL and TCR-Engineered Therapy
4.4.5. Radioligand and Radiopharmaceutical Therapy
4.4.5.1. Beta-Emitter Therapies
4.4.5.2. Alpha-Emitter Therapies
4.4.6. Therapeutic Cancer Vaccines and Oncolytic Viruses
4.4.7. Small-Molecule Targeted Therapy and Degraders
4.4.8. Subcutaneous and Oral Reformulation Technologies
4.5. Precision Oncology and Biomarker Landscape
4.5.1. Predictive Biomarkers and Companion Diagnostics
4.5.2. Tumour-Agnostic Approvals
4.5.3. Minimal Residual Disease and Treatment Monitoring
4.6. Clinical Pipeline Analysis
4.6.1. Late-Stage Pipeline by Modality
4.6.2. Late-Stage Pipeline by Indication
4.6.3. Attrition and Probability of Success Analysis
4.7. Patent Expiry and Biosimilar Outlook
4.7.1. Loss of Exclusivity Timeline for Major Oncology Biologics
4.7.2. Biosimilar Pipeline and Market Entry Dynamics
4.7.3. Reformulation as a Lifecycle Strategy
4.8. Pricing and Reimbursement Analysis
4.8.1. U.S. Pricing, Government Price Setting and Payer Coverage
4.8.2. European Health Technology Assessment Positions
4.8.3. China Volume-Based Procurement and Reimbursement Listing
4.8.4. Emerging Market Access and Pricing
4.9. Regulatory Landscape
4.9.1. Accelerated and Conditional Approval Pathways
4.9.2. Cell and Gene Therapy Regulation
4.9.3. Radiopharmaceutical Regulation and Isotope Handling
4.9.4. Post-Marketing Requirements and Confirmatory Trials
4.10. Manufacturing and Supply Chain Analysis
4.10.1. Biologics and Conjugation Capacity
4.10.2. Cell Therapy Manufacturing and Vein-to-Vein Time
4.10.3. Medical Isotope Supply
4.11. Licensing, Partnership and M&A Landscape
4.12. Value Chain Analysis
4.13. Patent Analysis
4.14. Porter's Five Forces Analysis
4.15. Industry Attractiveness Assessment

5. Market Dynamics

5.1. Drivers
5.1.1. Rising Global Cancer Incidence and Ageing Populations
5.1.2. Expansion of Antibody-Drug Conjugates and Bispecific Antibodies
5.1.3. Adoption of Biomarker-Guided Precision Oncology
5.1.4. Maturation of Cell Therapy and Radioligand Therapy
5.1.5. Widening Treatment Access across Emerging Markets
5.2. Restraints
5.2.1. Loss of Exclusivity on the Largest Products
5.2.2. Government Price-Setting and Health Technology Assessment Pressure
5.2.3. Complexity and Cost of Manufacturing Advanced Therapies
5.2.4. Late-Stage Clinical Attrition
5.3. Opportunities
5.3.1. Subcutaneous and Oral Reformulation of Established Biologics
5.3.2. Radioligand Therapy across New Tumour Targets
5.3.3. Allogeneic and In Vivo Cell Therapy Platforms
5.3.4. Biosimilar Entry Opening Volume in Emerging Markets
5.4. Challenges
5.4.1. Crowding around Validated Targets
5.4.2. Treatment Sequencing and Resistance
5.4.3. Access and Delivery Capacity for Complex Therapies
5.4.4. Toxicity Burden of Combination Regimens
5.5. Key Trends
5.5.1. Shift from Intravenous to Subcutaneous Administration
5.5.2. Advanced Modalities Moving into First-Line and Adjuvant Settings
5.5.3. Rise of China as a Source of Oncology Innovation
5.5.4. Convergence of Modalities within Combination Regimens

6. Cancer Therapy Market, by Therapy Class

6.1. Introduction
6.2. Targeted Therapy
6.2.1. Small-Molecule Inhibitors
6.2.1.1. Kinase Inhibitors
6.2.1.2. PARP Inhibitors
6.2.1.3. CDK4/6 Inhibitors
6.2.1.4. Other Pathway Inhibitors and Degraders
6.2.2. Monoclonal Antibodies
6.2.3. Antibody-Drug Conjugates
6.3. Immunotherapy
6.3.1. Immune Checkpoint Inhibitors
6.3.1.1. PD-1 Inhibitors
6.3.1.2. PD-L1 Inhibitors
6.3.1.3. CTLA-4 and Other Checkpoints
6.3.2. Bispecific Antibodies & T-Cell Engagers
6.3.3. Cell Therapies
6.3.3.1. CAR-T Therapies
6.3.3.2. TIL and TCR-Engineered Therapies
6.3.3.3. NK and Allogeneic Cell Therapies
6.3.4. Therapeutic Cancer Vaccines
6.3.5. Oncolytic Viruses and Cytokine Therapies
6.4. Chemotherapy
6.4.1. Platinum Compounds
6.4.2. Antimetabolites
6.4.3. Taxanes and Mitotic Inhibitors
6.4.4. Alkylating Agents and Anthracyclines
6.5. Hormonal Therapy
6.5.1. Aromatase Inhibitors and SERDs
6.5.2. Androgen Receptor Pathway Inhibitors
6.5.3. LHRH Agonists and Antagonists
6.6. Radiopharmaceutical Therapy
6.6.1. Beta-Emitting Radioligands
6.6.2. Alpha-Emitting Radioligands

7. Cancer Therapy Market, by Molecule Type

7.1. Introduction
7.2. Monoclonal Antibodies
7.3. Antibody-Drug Conjugates
7.4. Bispecific Antibodies & T-Cell Engagers
7.5. Small Molecules
7.6. Cell & Gene Therapies
7.7. Radioligands

8. Cancer Therapy Market, by Route of Administration

8.1. Introduction
8.2. Intravenous
8.3. Subcutaneous
8.4. Oral
8.5. Intratumoural & Other Routes

9. Cancer Therapy Market, by Line of Therapy

9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line & Later
9.5. Adjuvant & Neoadjuvant

10. Cancer Therapy Market, by Cancer Indication

10.1. Introduction
10.2. Lung Cancer
10.2.1. Non-Small Cell Lung Cancer
10.2.2. Small Cell Lung Cancer
10.3. Breast Cancer
10.3.1. HER2-Positive
10.3.2. HER2-Low and HER2-Negative
10.3.3. Triple-Negative
10.4. Haematological Malignancies
10.4.1. Multiple Myeloma
10.4.2. Lymphoma
10.4.3. Leukemia
10.5. Gastrointestinal Cancers
10.5.1. Colorectal Cancer
10.5.2. Gastric and Esophageal Cancer
10.5.3. Pancreatic and Hepatobiliary Cancer
10.6. Genitourinary Cancers
10.6.1. Prostate Cancer
10.6.2. Bladder and Urothelial Cancer
10.6.3. Renal Cell Carcinoma
10.7. Gynaecologic Cancers
10.8. Other Cancers
10.8.1. Melanoma and Skin Cancers
10.8.2. Head and Neck Cancers
10.8.3. Neuroendocrine Tumours
10.8.4. Central Nervous System Tumours

11. Cancer Therapy Market, by Treatment Setting

11.1. Introduction
11.2. Hospital Inpatient
11.3. Hospital Outpatient & Infusion Centers
11.4. Specialty Cancer Centers
11.5. Community Oncology Practices

12. Cancer Therapy Market, by Distribution Channel

12.1. Introduction
12.2. Hospital Pharmacies
12.3. Specialty Pharmacies
12.4. Retail Pharmacies

13. Cancer Therapy Market, by End User

13.1. Introduction
13.2. Hospitals & Cancer Centers
13.3. Specialty Clinics
13.4. Home & Ambulatory Care

14. Cancer Therapy Market, by Geography

14.1. Introduction
14.2. North America
14.2.1. U.S.
14.2.2. Canada
14.3. Europe
14.3.1. Germany
14.3.2. France
14.3.3. U.K.
14.3.4. Italy
14.3.5. Spain
14.3.6. Switzerland
14.3.7. Nordic Countries
14.3.8. Rest of Europe
14.4. Asia-Pacific
14.4.1. China
14.4.2. Japan
14.4.3. India
14.4.4. South Korea
14.4.5. Australia
14.4.6. Southeast Asia
14.4.7. Rest of Asia-Pacific
14.5. Latin America
14.5.1. Brazil
14.5.2. Mexico
14.5.3. Argentina
14.5.4. Colombia
14.5.5. Rest of Latin America
14.6. Middle East & Africa
14.6.1. Saudi Arabia
14.6.2. UAE
14.6.3. Israel
14.6.4. Egypt
14.6.5. South Africa
14.6.6. Rest of Middle East & Africa

15. Competitive Landscape

15.1. Overview
15.2. Key Growth Strategies
15.3. Competitive Benchmarking
15.4. Competitive Dashboard
15.4.1. Industry Leaders
15.4.2. Market Differentiators
15.4.3. Vanguards
15.4.4. Emerging Companies
15.5. Strategic Developments
15.5.1. Product Approvals and Label Expansions
15.5.2. Licensing and Collaboration Agreements
15.5.3. Acquisitions
15.5.4. Manufacturing and Capacity Investments
15.6. Market Share/Rank Analysis, by Key Player (2025)

16. Company Profiles

(Business Overview, Financial Overview, Product Portfolio, Strategic Developments, SWOT Analysis)
Large-Cap Oncology Portfolio Companies
16.1. Merck & Co., Inc.
16.2. Johnson & Johnson
16.3. F. Hoffmann-La Roche Ltd
16.4. AstraZeneca PLC
16.5. Bristol Myers Squibb Company
16.6. Pfizer Inc.
16.7. Novartis AG
16.8. Eli Lilly and Company
16.9. AbbVie Inc.
16.10. Amgen Inc.
16.11. Sanofi S.A.
16.12. GSK plc
Modality Specialists
16.13. Daiichi Sankyo Company, Limited
16.14. Gilead Sciences, Inc.
16.15. Takeda Pharmaceutical Company Limited
16.16. Regeneron Pharmaceuticals, Inc.
16.17. Genmab A/S
16.18. Legend Biotech Corporation
16.19. Advanced Accelerator Applications (Novartis)
Asia-Pacific Oncology Developers
16.20. BeiGene, Ltd. (BeOne Medicines)
16.21. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
16.22. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

17. Appendix

17.1. Related Reports
17.2. Customization Options

LIST OF TABLES

Table 1. Global Cancer Therapy Market Drivers: Impact Analysis (2026-2036)
Table 2. Global Cancer Therapy Market Restraints: Impact Analysis (2026-2036)
Table 3. Global Cancer Therapy Market Opportunities: Impact Analysis (2026-2036)
Table 4. Global Cancer Therapy Market Challenges: Impact Analysis (2026-2036)
Table 5. Global Cancer Incidence and Mortality, by Tumour Type
Table 6. Standard of Care by Major Cancer Indication and Line of Therapy
Table 7. Selected Late-Stage Oncology Pipeline Candidates, by Modality
Table 8. Loss of Exclusivity Timeline for Major Oncology Biologics
Table 9. Pricing and Reimbursement Mechanisms for Oncology Medicines, by Country/Region
Table 10. Key Regulatory Pathways Affecting the Cancer Therapy Market, by Country/Region
Table 11. Major Licensing, Partnership, and M&A Deals in Oncology
Table 12. Porter's Five Forces Analysis: Cancer Therapy Market
Table 13. Global Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 14. Global Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 15. Cancer Therapy Market for Targeted Therapy, by Country/Region, 2024-2036 (USD Million)
Table 16. Cancer Therapy Market for Small-Molecule Inhibitors, by Country/Region, 2024-2036 (USD Million)
Table 17. Cancer Therapy Market for Monoclonal Antibodies, by Country/Region, 2024-2036 (USD Million)
Table 18. Cancer Therapy Market for Antibody-Drug Conjugates, by Country/Region, 2024-2036 (USD Million)
Table 19. Global Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 20. Cancer Therapy Market for Immunotherapy, by Country/Region, 2024-2036 (USD Million)
Table 21. Cancer Therapy Market for Immune Checkpoint Inhibitors, by Country/Region, 2024-2036 (USD Million)
Table 22. Cancer Therapy Market for Bispecific Antibodies & T-Cell Engagers, by Country/Region, 2024-2036 (USD Million)
Table 23. Cancer Therapy Market for Cell Therapies, by Country/Region, 2024-2036 (USD Million)
Table 24. Cancer Therapy Market for Therapeutic Cancer Vaccines, by Country/Region, 2024-2036 (USD Million)
Table 25. Cancer Therapy Market for Oncolytic Viruses and Cytokine Therapies, by Country/Region, 2024-2036 (USD Million)
Table 26. Global Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 27. Cancer Therapy Market for Chemotherapy, by Country/Region, 2024-2036 (USD Million)
Table 28. Cancer Therapy Market for Platinum Compounds, by Country/Region, 2024-2036 (USD Million)
Table 29. Cancer Therapy Market for Antimetabolites, by Country/Region, 2024-2036 (USD Million)
Table 30. Cancer Therapy Market for Taxanes and Mitotic Inhibitors, by Country/Region, 2024-2036 (USD Million)
Table 31. Cancer Therapy Market for Alkylating Agents and Anthracyclines, by Country/Region, 2024-2036 (USD Million)
Table 32. Global Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 33. Cancer Therapy Market for Hormonal Therapy, by Country/Region, 2024-2036 (USD Million)
Table 34. Cancer Therapy Market for Aromatase Inhibitors and SERDs, by Country/Region, 2024-2036 (USD Million)
Table 35. Cancer Therapy Market for Androgen Receptor Pathway Inhibitors, by Country/Region, 2024-2036 (USD Million)
Table 36. Cancer Therapy Market for LHRH Agonists and Antagonists, by Country/Region, 2024-2036 (USD Million)
Table 37. Global Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 38. Cancer Therapy Market for Radiopharmaceutical Therapy, by Country/Region, 2024-2036 (USD Million)
Table 39. Cancer Therapy Market for Beta-Emitting Radioligands, by Country/Region, 2024-2036 (USD Million)
Table 40. Cancer Therapy Market for Alpha-Emitting Radioligands, by Country/Region, 2024-2036 (USD Million)
Table 41. Global Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 42. Cancer Therapy Market for Monoclonal Antibodies, by Country/Region, 2024-2036 (USD Million)
Table 43. Cancer Therapy Market for Antibody-Drug Conjugates, by Country/Region, 2024-2036 (USD Million)
Table 44. Cancer Therapy Market for Bispecific Antibodies & T-Cell Engagers, by Country/Region, 2024-2036 (USD Million)
Table 45. Cancer Therapy Market for Small Molecules, by Country/Region, 2024-2036 (USD Million)
Table 46. Cancer Therapy Market for Cell & Gene Therapies, by Country/Region, 2024-2036 (USD Million)
Table 47. Cancer Therapy Market for Radioligands, by Country/Region, 2024-2036 (USD Million)
Table 48. Global Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 49. Cancer Therapy Market for Intravenous, by Country/Region, 2024-2036 (USD Million)
Table 50. Cancer Therapy Market for Subcutaneous, by Country/Region, 2024-2036 (USD Million)
Table 51. Cancer Therapy Market for Oral, by Country/Region, 2024-2036 (USD Million)
Table 52. Cancer Therapy Market for Intratumoural & Other Routes, by Country/Region, 2024-2036 (USD Million)
Table 53. Global Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 54. Cancer Therapy Market for First Line, by Country/Region, 2024-2036 (USD Million)
Table 55. Cancer Therapy Market for Second Line, by Country/Region, 2024-2036 (USD Million)
Table 56. Cancer Therapy Market for Third Line & Later, by Country/Region, 2024-2036 (USD Million)
Table 57. Cancer Therapy Market for Adjuvant & Neoadjuvant, by Country/Region, 2024-2036 (USD Million)
Table 58. Global Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 59. Global Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 60. Cancer Therapy Market for Lung Cancer, by Country/Region, 2024-2036 (USD Million)
Table 61. Cancer Therapy Market for Non-Small Cell Lung Cancer, by Country/Region, 2024-2036 (USD Million)
Table 62. Cancer Therapy Market for Small Cell Lung Cancer, by Country/Region, 2024-2036 (USD Million)
Table 63. Global Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 64. Cancer Therapy Market for Breast Cancer, by Country/Region, 2024-2036 (USD Million)
Table 65. Cancer Therapy Market for HER2-Positive, by Country/Region, 2024-2036 (USD Million)
Table 66. Cancer Therapy Market for HER2-Low and HER2-Negative, by Country/Region, 2024-2036 (USD Million)
Table 67. Cancer Therapy Market for Triple-Negative, by Country/Region, 2024-2036 (USD Million)
Table 68. Global Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 69. Cancer Therapy Market for Haematological Malignancies, by Country/Region, 2024-2036 (USD Million)
Table 70. Cancer Therapy Market for Multiple Myeloma, by Country/Region, 2024-2036 (USD Million)
Table 71. Cancer Therapy Market for Lymphoma, by Country/Region, 2024-2036 (USD Million)
Table 72. Cancer Therapy Market for Leukemia, by Country/Region, 2024-2036 (USD Million)
Table 73. Global Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 74. Cancer Therapy Market for Gastrointestinal Cancers, by Country/Region, 2024-2036 (USD Million)
Table 75. Cancer Therapy Market for Colorectal Cancer, by Country/Region, 2024-2036 (USD Million)
Table 76. Cancer Therapy Market for Gastric and Esophageal Cancer, by Country/Region, 2024-2036 (USD Million)
Table 77. Cancer Therapy Market for Pancreatic and Hepatobiliary Cancer, by Country/Region, 2024-2036 (USD Million)
Table 78. Global Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 79. Cancer Therapy Market for Genitourinary Cancers, by Country/Region, 2024-2036 (USD Million)
Table 80. Cancer Therapy Market for Prostate Cancer, by Country/Region, 2024-2036 (USD Million)
Table 81. Cancer Therapy Market for Bladder and Urothelial Cancer, by Country/Region, 2024-2036 (USD Million)
Table 82. Cancer Therapy Market for Renal Cell Carcinoma, by Country/Region, 2024-2036 (USD Million)
Table 83. Cancer Therapy Market for Gynaecologic Cancers, by Country/Region, 2024-2036 (USD Million)
Table 84. Global Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 85. Cancer Therapy Market for Other Cancers, by Country/Region, 2024-2036 (USD Million)
Table 86. Cancer Therapy Market for Melanoma and Skin Cancers, by Country/Region, 2024-2036 (USD Million)
Table 87. Cancer Therapy Market for Head and Neck Cancers, by Country/Region, 2024-2036 (USD Million)
Table 88. Cancer Therapy Market for Neuroendocrine Tumours, by Country/Region, 2024-2036 (USD Million)
Table 89. Cancer Therapy Market for Central Nervous System Tumours, by Country/Region, 2024-2036 (USD Million)
Table 90. Global Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 91. Cancer Therapy Market for Hospital Inpatient, by Country/Region, 2024-2036 (USD Million)
Table 92. Cancer Therapy Market for Hospital Outpatient & Infusion Centers, by Country/Region, 2024-2036 (USD Million)
Table 93. Cancer Therapy Market for Specialty Cancer Centers, by Country/Region, 2024-2036 (USD Million)
Table 94. Cancer Therapy Market for Community Oncology Practices, by Country/Region, 2024-2036 (USD Million)
Table 95. Global Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 96. Cancer Therapy Market for Hospital Pharmacies, by Country/Region, 2024-2036 (USD Million)
Table 97. Cancer Therapy Market for Specialty Pharmacies, by Country/Region, 2024-2036 (USD Million)
Table 98. Cancer Therapy Market for Retail Pharmacies, by Country/Region, 2024-2036 (USD Million)
Table 99. Global Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 100. Cancer Therapy Market for Hospitals & Cancer Centers, by Country/Region, 2024-2036 (USD Million)
Table 101. Cancer Therapy Market for Specialty Clinics, by Country/Region, 2024-2036 (USD Million)
Table 102. Cancer Therapy Market for Home & Ambulatory Care, by Country/Region, 2024-2036 (USD Million)
Table 103. Global Cancer Therapy Market, by Region, 2024-2036 (USD Million)
Table 104. Global Cancer Therapy Market, by Country/Region, 2024-2036 (USD Million)
Table 105. North America: Cancer Therapy Market, by Country, 2024-2036 (USD Million)
Table 106. North America: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 107. North America: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 108. North America: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 109. North America: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 110. North America: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 111. North America: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 112. North America: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 113. North America: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 114. North America: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 115. North America: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 116. North America: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 117. North America: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 118. North America: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 119. North America: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 120. North America: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 121. North America: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 122. North America: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 123. North America: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 124. North America: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 125. U.S.: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 126. U.S.: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 127. U.S.: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 128. U.S.: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 129. U.S.: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 130. U.S.: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 131. U.S.: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 132. U.S.: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 133. U.S.: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 134. U.S.: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 135. U.S.: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 136. U.S.: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 137. U.S.: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 138. U.S.: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 139. U.S.: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 140. U.S.: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 141. U.S.: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 142. U.S.: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 143. U.S.: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 144. Canada: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 145. Canada: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 146. Canada: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 147. Canada: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 148. Canada: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 149. Canada: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 150. Canada: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 151. Canada: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 152. Canada: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 153. Canada: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 154. Canada: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 155. Canada: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 156. Canada: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 157. Canada: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 158. Canada: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 159. Canada: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 160. Canada: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 161. Canada: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 162. Canada: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 163. Europe: Cancer Therapy Market, by Country, 2024-2036 (USD Million)
Table 164. Europe: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 165. Europe: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 166. Europe: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 167. Europe: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 168. Europe: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 169. Europe: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 170. Europe: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 171. Europe: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 172. Europe: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 173. Europe: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 174. Europe: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 175. Europe: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 176. Europe: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 177. Europe: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 178. Europe: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 179. Europe: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 180. Europe: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 181. Europe: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 182. Europe: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 183. Germany: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 184. Germany: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 185. Germany: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 186. Germany: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 187. Germany: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 188. Germany: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 189. Germany: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 190. Germany: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 191. Germany: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 192. Germany: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 193. Germany: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 194. Germany: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 195. Germany: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 196. Germany: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 197. Germany: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 198. Germany: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 199. Germany: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 200. Germany: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 201. Germany: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 202. France: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 203. France: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 204. France: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 205. France: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 206. France: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 207. France: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 208. France: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 209. France: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 210. France: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 211. France: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 212. France: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 213. France: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 214. France: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 215. France: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 216. France: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 217. France: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 218. France: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 219. France: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 220. France: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 221. U.K.: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 222. U.K.: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 223. U.K.: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 224. U.K.: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 225. U.K.: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 226. U.K.: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 227. U.K.: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 228. U.K.: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 229. U.K.: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 230. U.K.: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 231. U.K.: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 232. U.K.: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 233. U.K.: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 234. U.K.: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 235. U.K.: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 236. U.K.: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 237. U.K.: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 238. U.K.: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 239. U.K.: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 240. Italy: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 241. Italy: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 242. Italy: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 243. Italy: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 244. Italy: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 245. Italy: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 246. Italy: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 247. Italy: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 248. Italy: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 249. Italy: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 250. Italy: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 251. Italy: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 252. Italy: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 253. Italy: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 254. Italy: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 255. Italy: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 256. Italy: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 257. Italy: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 258. Italy: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 259. Spain: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 260. Spain: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 261. Spain: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 262. Spain: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 263. Spain: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 264. Spain: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 265. Spain: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 266. Spain: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 267. Spain: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 268. Spain: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 269. Spain: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 270. Spain: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 271. Spain: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 272. Spain: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 273. Spain: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 274. Spain: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 275. Spain: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 276. Spain: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 277. Spain: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 278. Switzerland: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 279. Switzerland: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 280. Switzerland: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 281. Switzerland: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 282. Switzerland: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 283. Switzerland: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 284. Switzerland: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 285. Switzerland: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 286. Switzerland: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 287. Switzerland: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 288. Switzerland: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 289. Switzerland: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 290. Switzerland: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 291. Switzerland: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 292. Switzerland: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 293. Switzerland: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 294. Switzerland: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 295. Switzerland: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 296. Switzerland: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 297. Nordic Countries: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 298. Nordic Countries: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 299. Nordic Countries: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 300. Nordic Countries: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 301. Nordic Countries: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 302. Nordic Countries: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 303. Nordic Countries: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 304. Nordic Countries: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 305. Nordic Countries: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 306. Nordic Countries: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 307. Nordic Countries: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 308. Nordic Countries: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 309. Nordic Countries: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 310. Nordic Countries: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 311. Nordic Countries: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 312. Nordic Countries: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 313. Nordic Countries: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 314. Nordic Countries: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 315. Nordic Countries: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 316. Rest of Europe: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 317. Rest of Europe: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 318. Rest of Europe: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 319. Rest of Europe: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 320. Rest of Europe: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 321. Rest of Europe: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 322. Rest of Europe: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 323. Rest of Europe: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 324. Rest of Europe: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 325. Rest of Europe: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 326. Rest of Europe: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 327. Rest of Europe: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 328. Rest of Europe: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 329. Rest of Europe: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 330. Rest of Europe: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 331. Rest of Europe: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 332. Rest of Europe: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 333. Rest of Europe: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 334. Rest of Europe: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 335. Asia-Pacific: Cancer Therapy Market, by Country, 2024-2036 (USD Million)
Table 336. Asia-Pacific: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 337. Asia-Pacific: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 338. Asia-Pacific: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 339. Asia-Pacific: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 340. Asia-Pacific: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 341. Asia-Pacific: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 342. Asia-Pacific: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 343. Asia-Pacific: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 344. Asia-Pacific: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 345. Asia-Pacific: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 346. Asia-Pacific: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 347. Asia-Pacific: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 348. Asia-Pacific: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 349. Asia-Pacific: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 350. Asia-Pacific: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 351. Asia-Pacific: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 352. Asia-Pacific: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 353. Asia-Pacific: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 354. Asia-Pacific: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 355. China: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 356. China: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 357. China: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 358. China: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 359. China: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 360. China: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 361. China: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 362. China: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 363. China: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 364. China: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 365. China: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 366. China: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 367. China: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 368. China: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 369. China: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 370. China: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 371. China: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 372. China: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 373. China: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 374. Japan: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 375. Japan: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 376. Japan: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 377. Japan: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 378. Japan: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 379. Japan: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 380. Japan: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 381. Japan: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 382. Japan: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 383. Japan: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 384. Japan: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 385. Japan: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 386. Japan: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 387. Japan: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 388. Japan: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 389. Japan: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 390. Japan: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 391. Japan: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 392. Japan: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 393. India: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 394. India: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 395. India: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 396. India: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 397. India: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 398. India: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 399. India: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 400. India: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 401. India: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 402. India: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 403. India: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 404. India: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 405. India: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 406. India: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 407. India: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 408. India: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 409. India: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 410. India: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 411. India: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 412. South Korea: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 413. South Korea: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 414. South Korea: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 415. South Korea: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 416. South Korea: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 417. South Korea: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 418. South Korea: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 419. South Korea: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 420. South Korea: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 421. South Korea: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 422. South Korea: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 423. South Korea: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 424. South Korea: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 425. South Korea: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 426. South Korea: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 427. South Korea: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 428. South Korea: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 429. South Korea: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 430. South Korea: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 431. Australia: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 432. Australia: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 433. Australia: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 434. Australia: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 435. Australia: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 436. Australia: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 437. Australia: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 438. Australia: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 439. Australia: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 440. Australia: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 441. Australia: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 442. Australia: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 443. Australia: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 444. Australia: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 445. Australia: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 446. Australia: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 447. Australia: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 448. Australia: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 449. Australia: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 450. Southeast Asia: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 451. Southeast Asia: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 452. Southeast Asia: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 453. Southeast Asia: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 454. Southeast Asia: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 455. Southeast Asia: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 456. Southeast Asia: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 457. Southeast Asia: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 458. Southeast Asia: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 459. Southeast Asia: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 460. Southeast Asia: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 461. Southeast Asia: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 462. Southeast Asia: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 463. Southeast Asia: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 464. Southeast Asia: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 465. Southeast Asia: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 466. Southeast Asia: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 467. Southeast Asia: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 468. Southeast Asia: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 469. Rest of Asia-Pacific: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 470. Rest of Asia-Pacific: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 471. Rest of Asia-Pacific: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 472. Rest of Asia-Pacific: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 473. Rest of Asia-Pacific: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 474. Rest of Asia-Pacific: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 475. Rest of Asia-Pacific: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 476. Rest of Asia-Pacific: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 477. Rest of Asia-Pacific: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 478. Rest of Asia-Pacific: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 479. Rest of Asia-Pacific: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 480. Rest of Asia-Pacific: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 481. Rest of Asia-Pacific: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 482. Rest of Asia-Pacific: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 483. Rest of Asia-Pacific: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 484. Rest of Asia-Pacific: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 485. Rest of Asia-Pacific: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 486. Rest of Asia-Pacific: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 487. Rest of Asia-Pacific: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 488. Latin America: Cancer Therapy Market, by Country, 2024-2036 (USD Million)
Table 489. Latin America: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 490. Latin America: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 491. Latin America: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 492. Latin America: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 493. Latin America: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 494. Latin America: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 495. Latin America: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 496. Latin America: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 497. Latin America: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 498. Latin America: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 499. Latin America: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 500. Latin America: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 501. Latin America: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 502. Latin America: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 503. Latin America: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 504. Latin America: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 505. Latin America: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 506. Latin America: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 507. Latin America: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 508. Brazil: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 509. Brazil: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 510. Brazil: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 511. Brazil: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 512. Brazil: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 513. Brazil: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 514. Brazil: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 515. Brazil: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 516. Brazil: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 517. Brazil: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 518. Brazil: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 519. Brazil: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 520. Brazil: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 521. Brazil: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 522. Brazil: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 523. Brazil: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 524. Brazil: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 525. Brazil: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 526. Brazil: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 527. Mexico: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 528. Mexico: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 529. Mexico: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 530. Mexico: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 531. Mexico: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 532. Mexico: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 533. Mexico: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 534. Mexico: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 535. Mexico: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 536. Mexico: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 537. Mexico: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 538. Mexico: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 539. Mexico: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 540. Mexico: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 541. Mexico: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 542. Mexico: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 543. Mexico: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 544. Mexico: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 545. Mexico: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 546. Argentina: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 547. Argentina: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 548. Argentina: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 549. Argentina: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 550. Argentina: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 551. Argentina: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 552. Argentina: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 553. Argentina: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 554. Argentina: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 555. Argentina: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 556. Argentina: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 557. Argentina: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 558. Argentina: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 559. Argentina: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 560. Argentina: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 561. Argentina: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 562. Argentina: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 563. Argentina: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 564. Argentina: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 565. Colombia: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 566. Colombia: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 567. Colombia: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 568. Colombia: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 569. Colombia: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 570. Colombia: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 571. Colombia: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 572. Colombia: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 573. Colombia: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 574. Colombia: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 575. Colombia: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 576. Colombia: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 577. Colombia: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 578. Colombia: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 579. Colombia: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 580. Colombia: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 581. Colombia: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 582. Colombia: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 583. Colombia: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 584. Rest of Latin America: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 585. Rest of Latin America: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 586. Rest of Latin America: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 587. Rest of Latin America: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 588. Rest of Latin America: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 589. Rest of Latin America: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 590. Rest of Latin America: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 591. Rest of Latin America: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 592. Rest of Latin America: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 593. Rest of Latin America: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 594. Rest of Latin America: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 595. Rest of Latin America: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 596. Rest of Latin America: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 597. Rest of Latin America: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 598. Rest of Latin America: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 599. Rest of Latin America: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 600. Rest of Latin America: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 601. Rest of Latin America: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 602. Rest of Latin America: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 603. Middle East & Africa: Cancer Therapy Market, by Country, 2024-2036 (USD Million)
Table 604. Middle East & Africa: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 605. Middle East & Africa: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 606. Middle East & Africa: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 607. Middle East & Africa: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 608. Middle East & Africa: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 609. Middle East & Africa: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 610. Middle East & Africa: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 611. Middle East & Africa: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 612. Middle East & Africa: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 613. Middle East & Africa: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 614. Middle East & Africa: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 615. Middle East & Africa: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 616. Middle East & Africa: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 617. Middle East & Africa: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 618. Middle East & Africa: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 619. Middle East & Africa: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 620. Middle East & Africa: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 621. Middle East & Africa: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 622. Middle East & Africa: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 623. Saudi Arabia: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 624. Saudi Arabia: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 625. Saudi Arabia: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 626. Saudi Arabia: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 627. Saudi Arabia: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 628. Saudi Arabia: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 629. Saudi Arabia: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 630. Saudi Arabia: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 631. Saudi Arabia: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 632. Saudi Arabia: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 633. Saudi Arabia: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 634. Saudi Arabia: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 635. Saudi Arabia: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 636. Saudi Arabia: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 637. Saudi Arabia: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 638. Saudi Arabia: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 639. Saudi Arabia: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 640. Saudi Arabia: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 641. Saudi Arabia: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 642. UAE: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 643. UAE: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 644. UAE: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 645. UAE: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 646. UAE: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 647. UAE: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 648. UAE: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 649. UAE: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 650. UAE: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 651. UAE: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 652. UAE: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 653. UAE: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 654. UAE: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 655. UAE: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 656. UAE: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 657. UAE: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 658. UAE: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 659. UAE: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 660. UAE: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 661. Israel: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 662. Israel: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 663. Israel: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 664. Israel: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 665. Israel: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 666. Israel: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 667. Israel: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 668. Israel: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 669. Israel: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 670. Israel: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 671. Israel: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 672. Israel: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 673. Israel: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 674. Israel: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 675. Israel: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 676. Israel: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 677. Israel: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 678. Israel: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 679. Israel: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 680. Egypt: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 681. Egypt: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 682. Egypt: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 683. Egypt: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 684. Egypt: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 685. Egypt: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 686. Egypt: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 687. Egypt: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 688. Egypt: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 689. Egypt: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 690. Egypt: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 691. Egypt: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 692. Egypt: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 693. Egypt: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 694. Egypt: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 695. Egypt: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 696. Egypt: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 697. Egypt: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 698. Egypt: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 699. South Africa: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 700. South Africa: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 701. South Africa: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 702. South Africa: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 703. South Africa: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 704. South Africa: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 705. South Africa: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 706. South Africa: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 707. South Africa: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 708. South Africa: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 709. South Africa: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 710. South Africa: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 711. South Africa: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 712. South Africa: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 713. South Africa: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 714. South Africa: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 715. South Africa: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 716. South Africa: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 717. South Africa: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 718. Rest of Middle East & Africa: Cancer Therapy Market, by Therapy Class, 2024-2036 (USD Million)
Table 719. Rest of Middle East & Africa: Cancer Therapy Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 720. Rest of Middle East & Africa: Cancer Therapy Market for Immunotherapy, by Type, 2024-2036 (USD Million)
Table 721. Rest of Middle East & Africa: Cancer Therapy Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 722. Rest of Middle East & Africa: Cancer Therapy Market for Hormonal Therapy, by Type, 2024-2036 (USD Million)
Table 723. Rest of Middle East & Africa: Cancer Therapy Market for Radiopharmaceutical Therapy, by Type, 2024-2036 (USD Million)
Table 724. Rest of Middle East & Africa: Cancer Therapy Market, by Molecule Type, 2024-2036 (USD Million)
Table 725. Rest of Middle East & Africa: Cancer Therapy Market, by Route of Administration, 2024-2036 (USD Million)
Table 726. Rest of Middle East & Africa: Cancer Therapy Market, by Line of Therapy, 2024-2036 (USD Million)
Table 727. Rest of Middle East & Africa: Cancer Therapy Market, by Cancer Indication, 2024-2036 (USD Million)
Table 728. Rest of Middle East & Africa: Cancer Therapy Market for Lung Cancer, by Type, 2024-2036 (USD Million)
Table 729. Rest of Middle East & Africa: Cancer Therapy Market for Breast Cancer, by Type, 2024-2036 (USD Million)
Table 730. Rest of Middle East & Africa: Cancer Therapy Market for Haematological Malignancies, by Type, 2024-2036 (USD Million)
Table 731. Rest of Middle East & Africa: Cancer Therapy Market for Gastrointestinal Cancers, by Type, 2024-2036 (USD Million)
Table 732. Rest of Middle East & Africa: Cancer Therapy Market for Genitourinary Cancers, by Type, 2024-2036 (USD Million)
Table 733. Rest of Middle East & Africa: Cancer Therapy Market for Other Cancers, by Type, 2024-2036 (USD Million)
Table 734. Rest of Middle East & Africa: Cancer Therapy Market, by Treatment Setting, 2024-2036 (USD Million)
Table 735. Rest of Middle East & Africa: Cancer Therapy Market, by Distribution Channel, 2024-2036 (USD Million)
Table 736. Rest of Middle East & Africa: Cancer Therapy Market, by End User, 2024-2036 (USD Million)
Table 737. Cancer Therapy Market: Key Growth Strategies Adopted by Leading Players (2024-2026)
Table 738. Cancer Therapy Market: Strategic Developments, by Company (2024-2026)
Table 739. Cancer Therapy Market: Competitive Benchmarking
Table 740. Cancer Therapy Market: Market Share/Ranking Analysis, by Key Player (2025)
Table 741. Merck & Co., Inc.: Product Portfolio
Table 742. Merck & Co., Inc.: Strategic Developments
Table 743. Johnson & Johnson: Product Portfolio
Table 744. Johnson & Johnson: Strategic Developments
Table 745. F. Hoffmann-La Roche Ltd: Product Portfolio
Table 746. F. Hoffmann-La Roche Ltd: Strategic Developments
Table 747. AstraZeneca PLC: Product Portfolio
Table 748. AstraZeneca PLC: Strategic Developments
Table 749. Bristol Myers Squibb Company: Product Portfolio
Table 750. Bristol Myers Squibb Company: Strategic Developments
Table 751. Pfizer Inc.: Product Portfolio
Table 752. Pfizer Inc.: Strategic Developments
Table 753. Novartis AG: Product Portfolio
Table 754. Novartis AG: Strategic Developments
Table 755. Eli Lilly and Company: Product Portfolio
Table 756. Eli Lilly and Company: Strategic Developments
Table 757. AbbVie Inc.: Product Portfolio
Table 758. AbbVie Inc.: Strategic Developments
Table 759. Amgen Inc.: Product Portfolio
Table 760. Amgen Inc.: Strategic Developments
Table 761. Sanofi S.A.: Product Portfolio
Table 762. Sanofi S.A.: Strategic Developments
Table 763. GSK plc: Product Portfolio
Table 764. GSK plc: Strategic Developments
Table 765. Daiichi Sankyo Company, Limited: Product Portfolio
Table 766. Daiichi Sankyo Company, Limited: Strategic Developments
Table 767. Gilead Sciences, Inc.: Product Portfolio
Table 768. Gilead Sciences, Inc.: Strategic Developments
Table 769. Takeda Pharmaceutical Company Limited: Product Portfolio
Table 770. Takeda Pharmaceutical Company Limited: Strategic Developments
Table 771. Regeneron Pharmaceuticals, Inc.: Product Portfolio
Table 772. Regeneron Pharmaceuticals, Inc.: Strategic Developments
Table 773. Genmab A/S: Product Portfolio
Table 774. Genmab A/S: Strategic Developments
Table 775. Legend Biotech Corporation: Product Portfolio
Table 776. Legend Biotech Corporation: Strategic Developments
Table 777. Advanced Accelerator Applications (Novartis): Product Portfolio
Table 778. Advanced Accelerator Applications (Novartis): Strategic Developments
Table 779. BeiGene, Ltd. (BeOne Medicines): Product Portfolio
Table 780. BeiGene, Ltd. (BeOne Medicines): Strategic Developments
Table 781. Jiangsu Hengrui Pharmaceuticals Co., Ltd.: Product Portfolio
Table 782. Jiangsu Hengrui Pharmaceuticals Co., Ltd.: Strategic Developments
Table 783. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: Product Portfolio
Table 784. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: Strategic Developments
Table 785. Available Customization Options
Table 786. Available Related Reports

LIST OF FIGURES

Figure 1. Research Process
Figure 2. Key Secondary Sources
Figure 3. Primary Research Techniques
Figure 4. Key Executives Interviewed
Figure 5. Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6. Market Sizing and Growth Forecast Approach
Figure 7. Executive Summary: Global Cancer Therapy Market Size, 2024-2036 (USD Million)
Figure 8. Executive Summary: Global Cancer Therapy Market, by Therapy Class, 2026 vs. 2036 (USD Million)
Figure 9. Executive Summary: Global Cancer Therapy Market, by Molecule Type, 2026 vs. 2036 (USD Million)
Figure 10. Executive Summary: Global Cancer Therapy Market, by Route of Administration, 2026 vs. 2036 (USD Million)
Figure 11. Executive Summary: Global Cancer Therapy Market, by Line of Therapy, 2026 vs. 2036 (USD Million)
Figure 12. Executive Summary: Global Cancer Therapy Market, by Cancer Indication, 2026 vs. 2036 (USD Million)
Figure 13. Executive Summary: Global Cancer Therapy Market, by Treatment Setting, 2026 vs. 2036 (USD Million)
Figure 14. Executive Summary: Global Cancer Therapy Market, by Distribution Channel, 2026 vs. 2036 (USD Million)
Figure 15. Executive Summary: Global Cancer Therapy Market, by End User, 2026 vs. 2036 (USD Million)
Figure 16. Executive Summary: Global Cancer Therapy Market, by Region, 2026 vs. 2036 (USD Million)
Figure 17. Executive Summary: Competitive Landscape of the Cancer Therapy Market
Figure 18. Factors Impacting the Growth of the Cancer Therapy Market
Figure 19. Cancer Therapy Market Ecosystem
Figure 20. Projected Global New Cancer Cases, 2022-2050
Figure 21. Cancer Therapy Modality Landscape
Figure 22. Value Chain Analysis: Cancer Therapy Market
Figure 23. Cell Therapy Vein-to-Vein Process and Manufacturing Timeline
Figure 24. Global Cancer Therapy Market, by Therapy Class, 2026 vs. 2036 (USD Million)
Figure 25. Global Cancer Therapy Market, by Molecule Type, 2026 vs. 2036 (USD Million)
Figure 26. Global Cancer Therapy Market, by Route of Administration, 2026 vs. 2036 (USD Million)
Figure 27. Global Cancer Therapy Market, by Line of Therapy, 2026 vs. 2036 (USD Million)
Figure 28. Global Cancer Therapy Market, by Cancer Indication, 2026 vs. 2036 (USD Million)
Figure 29. Global Cancer Therapy Market, by Treatment Setting, 2026 vs. 2036 (USD Million)
Figure 30. Global Cancer Therapy Market, by Distribution Channel, 2026 vs. 2036 (USD Million)
Figure 31. Global Cancer Therapy Market, by End User, 2026 vs. 2036 (USD Million)
Figure 32. Global Cancer Therapy Market, by Region, 2026 vs. 2036 (USD Million)
Figure 33. North America: Cancer Therapy Market Snapshot
Figure 34. Europe: Cancer Therapy Market Snapshot
Figure 35. Asia-Pacific: Cancer Therapy Market Snapshot
Figure 36. Latin America: Cancer Therapy Market Snapshot
Figure 37. Middle East & Africa: Cancer Therapy Market Snapshot
Figure 38. Key Growth Strategies Adopted by Leading Players in the Cancer Therapy Market (2024-2026)
Figure 39. Cancer Therapy Market: Competitive Dashboard
Figure 40. Cancer Therapy Market Share/Ranking Analysis, by Key Player (2025)
Figure 41. Merck & Co., Inc.: SWOT Analysis
Figure 42. Johnson & Johnson: SWOT Analysis
Figure 43. F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 44. AstraZeneca PLC: SWOT Analysis
Figure 45. Bristol Myers Squibb Company: SWOT Analysis
Figure 46. Pfizer Inc.: SWOT Analysis
Figure 47. Novartis AG: SWOT Analysis
Figure 48. Eli Lilly and Company: SWOT Analysis
Figure 49. AbbVie Inc.: SWOT Analysis
Figure 50. Amgen Inc.: SWOT Analysis
Figure 51. Sanofi S.A.: SWOT Analysis
Figure 52. GSK plc: SWOT Analysis
Figure 53. Daiichi Sankyo Company, Limited: SWOT Analysis
Figure 54. Gilead Sciences, Inc.: SWOT Analysis
Figure 55. Takeda Pharmaceutical Company Limited: SWOT Analysis
Figure 56. Regeneron Pharmaceuticals, Inc.: SWOT Analysis
Figure 57. Genmab A/S: SWOT Analysis
Figure 58. Legend Biotech Corporation: SWOT Analysis
Figure 59. Advanced Accelerator Applications (Novartis): SWOT Analysis
Figure 60. BeiGene, Ltd. (BeOne Medicines): SWOT Analysis
Figure 61. Jiangsu Hengrui Pharmaceuticals Co., Ltd.: SWOT Analysis
Figure 62. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: SWOT Analysis

Companies Mentioned

Merck & Co., Inc.
Johnson & Johnson
F. Hoffmann-La Roche Ltd
AstraZeneca PLC
Bristol Myers Squibb Company
Pfizer Inc.
Novartis AG
Eli Lilly and Company
AbbVie Inc.
Amgen Inc.
Sanofi S.A.
GSK plc
Daiichi Sankyo Company, Limited
Gilead Sciences, Inc.
Takeda Pharmaceutical Company Limited
Regeneron Pharmaceuticals, Inc.
Genmab A/S
Legend Biotech Corporation
Advanced Accelerator Applications
BeiGene, Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€3848EUR$4,175USD£3,242GBP
1 - 5 USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a 1-5 user license, allowing up to five users have access to the product.	€5414EUR$5,875USD£4,562GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€7258EUR$7,875USD£6,115GBP

Cancer Therapy Market Size, Share, Forecast & Trends Analysis - Global Forecast to 2036

Market Dynamics

Segment Analysis

Regional Analysis

Competitive Landscape

How This Report Helps

Key Questions Answered

Table of Contents

Companies Mentioned

Market Dynamics

Segment Analysis

Regional Analysis

Competitive Landscape

How This Report Helps

Key Questions Answered

Table of Contents

Companies Mentioned

Related Topics

Related Reports

Bone Metastasis in Solid Tumors - Market Insight, Epidemiology, and Market Forecast - 2036

Esophageal Cancer - Market Insight, Epidemiology, and Market Forecast - 2036

Radioligand Therapy Market - Global Forecast to 2036

Checkpoint Inhibitor Refractory Cancer - Market Insight, Epidemiology, and Market Forecast - 2036

KRAS Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2036